

Package leaflet: Information for the patient

Cabazitaxel MSN 60 mg concentrate and solvent for solution for infusion

cabazitaxel

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Cabazitaxel MSN is and what it is used for
2. What you need to know before you are given Cabazitaxel MSN
3. How to use Cabazitaxel MSN
4. Possible side effects
5. How to store Cabazitaxel MSN
6. Contents of the pack and other information

1. What Cabazitaxel MSN is and what it is used for

The name of your medicine is Cabazitaxel MSN. Its common name is cabazitaxel. It belongs to a group of medicines called “taxanes” used to treat cancers.

Cabazitaxel MSN is used to treat prostate cancer that has progressed after having had other chemotherapy. It works by stopping cells from growing and multiplying.

As part of your treatment, you will also take a corticosteroid medicine (prednisone or prednisolone) by mouth every day. Ask your doctor to give you information about this other medicine.

2. What you need to know before you are given Cabazitaxel MSN

Do not use Cabazitaxel MSN if:

- you are allergic (hypersensitive) to cabazitaxel, to other taxanes, or polysorbate 80 or any of the other excipients of this medicine (listed in section 6),
- the number of your white blood cells is too low (neutrophil counts less than or equal to 1,500 /mm³),
- you have severe abnormal liver function,
- you have recently received or are about to receive a vaccine against yellow fever.

You should not be given Cabazitaxel MSN if any of the above apply to you. If you are not sure, talk to your doctor before having Cabazitaxel MSN.

Warnings and precautions

Before each treatment with Cabazitaxel MSN, you will have blood tests to check that you have enough blood cells and sufficient liver and kidney functions to receive Cabazitaxel MSN.

Tell your doctor immediately if:

- you have fever. During treatment with Cabazitaxel MSN, it is more likely that your white blood cell count may be reduced. Your doctor will monitor your blood and general condition for signs of infections. He/she may give you other medicines to maintain the number of your blood cells. People with low blood counts can develop life-threatening infections. The earliest sign of infection may be fever, so if you experience fever, tell your doctor right away.
- you have ever had any allergies. Serious allergic reactions can occur during treatment with Cabazitaxel MSN.
- you have severe or long-lasting diarrhoea, you feel sick (nausea) or you are being sick (vomiting). Any of these events could cause severe dehydration. Your doctor may need to treat you.
- you have feeling of numbness, tingling, burning or decreased sensation in your hands or feet.
- you have any bleeding problems from the gut or have changes in the colour of your stool or stomach pain. If the bleeding or pain is severe, your doctor will stop your treatment with Cabazitaxel MSN. This is because Cabazitaxel MSN may increase the risk of bleeding or developing holes in the gut wall.
- you have kidney problems.
- you have yellowing of the skin and eyes, darkening of the urine, severe nausea (feeling sick) or vomiting, as they could be signs or symptoms of liver problems.
- you experience any significant increase or decrease in daily urinary volume.
- you have blood in your urine.

If any of the above applies to you, tell your doctor immediately. Your doctor may reduce the dose of Cabazitaxel MSN or stop the treatment.

Other medicines and Cabazitaxel MSN

Please tell your doctor, pharmacist or nurse if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription. This is because some medicines can affect the way Cabazitaxel MSN works or Cabazitaxel MSN can affect how other medicines work. These medicines include the following:

- ketoconazole, rifampicin (for infections);
- carbamazepine, phenobarbital or phenytoin (for seizures);
- St John's Wort (*Hypericum perforatum*) (herbal remedy for depression and other conditions);
- statins (such as simvastatin, lovastatin, atorvastatin, rosuvastatin, or pravastatin) (for reducing the cholesterol in your blood);
- valsartan (for hypertension);
- repaglinide (for diabetes).

Talk to your doctor before getting vaccinations while you are receiving Cabazitaxel MSN.

Pregnancy, breast-feeding and fertility

Cabazitaxel MSN should not be used in pregnant women or women of childbearing age not using contraception.

Cabazitaxel MSN should not be used during breast-feeding.

Use a condom during sex if your partner is or could become pregnant. Cabazitaxel MSN could be present in your semen and may affect the foetus. You are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because Cabazitaxel MSN may alter male fertility.

Driving and using machines

You may feel tired or dizzy when having this medicine. If this happens, do not drive or use any tools or machines until you feel better.

Cabazitaxel MSN contains ethanol (alcohol)

This medicine contains 573 mg of alcohol (ethanol) in each solvent vial. The amount in the dose of this medicine is equivalent to less than 11 ml beer or 5 ml wine. The small amount of alcohol in this medicine will not have any noticeable effects. If you are addicted to alcohol, have liver disease or epilepsy, talk to your doctor or pharmacist before taking this medicine.

Cabazitaxel MSN contains polysorbate 80

Polysorbates can have an effect on your circulation and heart (e.g., low blood pressure, heart beat changes).

3. How to use Cabazitaxel MSN Instructions for use

Anti-allergic medicines will be given to you before you have Cabazitaxel MSN to reduce the risk of allergic reactions.

- Cabazitaxel MSN will be given to you by a doctor or a nurse.
- Cabazitaxel MSN must be prepared (diluted) before it is given. Practical information for handling and administration of Cabazitaxel MSN for doctors, nurses and pharmacists is provided with this leaflet.
- Cabazitaxel MSN will be given by a drip (infusion) into one of your veins (intravenous use) in hospital for about an hour.
- As part of your treatment, you will also take a corticosteroid medicine (prednisone or prednisolone) by mouth every day.

How much and how often to have

- The usual dose depends on your body surface area. Your doctor will calculate your body surface area in square meters (m²) and will decide the dose you should have.
- You will usually have an infusion once every 3 weeks.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss these with you and will explain the potential risks and benefits of your treatment.

See a doctor immediately if you notice any of the following side effects:

- fever (high temperature). This is common (may affect up to 1 in 10 people).
- severe loss of body fluids (dehydration). This is common (may affect up to 1 in 10 people). This can occur if you have severe or long-lasting diarrhoea, or fever, or if you are being sick (vomiting).
- severe stomach pain or stomach pain that doesn't go away. This can occur if you have a hole in the stomach, food pipe, gut or bowel (gastrointestinal perforation). This can lead to death.

If any of the above applies to you, tell your doctor immediately.

Other side effects include:

Very common (may affect more than 1 in 10 people):

- decrease in the number of red (anaemia), or white blood cells (which are important in fighting infection)
- decrease in the number of platelets (which results in increased risk of bleeding)
- loss of appetite (anorexia)
- stomach upsets including feeling sick (nausea), being sick (vomiting), diarrhoea or constipation
- back pain
- blood in the urine
- feeling tired, weak or lack of energy.

Common (may affect up to 1 in 10 people):

- alteration of taste
- shortness of breath
- cough
- abdominal pain
- short term hair loss (in most cases normal hair growth should return)
- joint pain
- urinary tract infection
- lack of white blood cells associated with fever and infection
- feeling of numbness, tingling, burning or decreased sensations in hands and feet
- dizziness
- headache
- decrease or increase in blood pressure
- uncomfortable feeling in the stomach, heart burn or belching
- stomach pain
- haemorrhoids
- muscle spasm
- painful or frequent urination
- urinary incontinence
- kidney disease or problems
- sore in the mouth or on lips
- infections or risk of infections
- high blood sugar
- insomnia
- mental confusion
- feeling anxious
- abnormal feeling or loss of sensation or pain in hands and feet
- trouble with balance
- rapid or irregular heartbeat
- blood clot in the leg or in the lung
- skin feeling flushed
- pain in mouth or throat
- rectal bleeding
- muscle discomfort, aches weakness or pain
- swelling of the feet or legs
- chills.

Uncommon (may affect up to 1 in 100 people):

- low blood potassium
- ringing in the ear
- skin feeling hot
- redness of the skin
- nail disorder (change in the colour of your nails; nails may detach)
- inflammation of the bladder, which can occur when your bladder has been previously exposed to radiation therapy (cystitis due to radiation recall phenomenon).

Frequency not known (cannot be estimated from the available data):

- interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing).

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system](#) listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Cabazitaxel MSN

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the outer carton and on the label of the vials after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Information about storage and the time to use Cabazitaxel MSN, once it has been diluted and is ready to use, are described in the section “PRACTICAL INFORMATION FOR MEDICAL OR HEALTHCARE PROFESSIONALS ON PREPARATION, ADMINISTRATION AND HANDLING OF Cabazitaxel MSN“.

Any unused product or waste material should be disposed of in accordance with local requirements. These measures will help to protect the environment.

6. Contents of the pack and other information

What Cabazitaxel MSN contains

The active substance is cabazitaxel. One ml of concentrate contains 40 mg cabazitaxel. Each vial of concentrate contains 60 mg cabazitaxel.

The other ingredients are polysorbate 80 and acid citric in the concentrate, and ethanol 96% and water for injections in the solvent (see section 2 “Cabazitaxel MSN contains alcohol”).

Note: Both the Cabazitaxel MSN 60 mg/1.5 ml concentrate vial (fill volume: 73.2 mg of cabazitaxel/1.83 ml) and the solvent vial (fill volume: 5.67 ml) contain an overfill to compensate for liquid loss during preparation. This overfill ensures that after dilution with the **ENTIRE** contents of the accompanying solvent, there is solution containing 10 mg/ml cabazitaxel.

What Cabazitaxel MSN looks like and contents of the pack

Cabazitaxel MSN is a concentrate and solvent for solution for infusion (sterile concentrate).

The concentrate is a clear colorless to pale yellow viscous solution.

The solvent is a clear and colourless solution.

One pack of Cabazitaxel MSN contains:

- One single use clear glass vial, closed with a chlorobutyl rubber closure sealed by an aluminium cap with a plastic flip-off cover, containing 1.5 ml (nominal volume) concentrate.
- One single use clear glass vial, closed with a chlorobutyl rubber closure sealed by an aluminium cap with a plastic flip-off cover, containing 4.5 ml (nominal volume) solvent.

Marketing Authorisation Holder

MSN Labs Europe Limited,
KW20A, Corradino Park,
Paola PLA 3000, Malta

Manufacturer

Pharmadox Healthcare Ltd,

KW20A Kordin Industrial Park,
Paola, PLA3000,
Malta

This leaflet was last revised in

This medicinal product is authorised in the Member States of the EEA under the following names:

Denmark	Cabazitaxel Medical Valley
Finland	Cabazitaxel Medical Valley 60 mg infuusiokonsentraatti ja liuotin, liuosta varten
Germany	Cabazitaxel AXiromed 60 mg Konzentrat und Lösung zur Herstellung einer Infusionslösung
Ireland	Cabazitaxel MSN
Netherlands	Cabazitaxel Vivanta 60 mg concentraat en oplosmiddel voor oplossing voor infusie
Norway	Cabazitaxel Medical Valley
Poland	Cabazitaxel Medical Valley
Spain	Cabazitaxel Vivanta 60 mg concentrado y disolvente para solución para perfusion EFG
Sweden	Cabazitaxel Medical Valley 60 mg koncentrat och vätska till infusionsvätska, lösning

The following information is intended for healthcare professionals only.

PRACTICAL INFORMATION FOR MEDICAL OR HEALTHCARE PROFESSIONALS ON PREPARATION, ADMINISTRATION AND HANDLING OF Cabazitaxel MSN 60 mg CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION

This information supplements sections 3 and 5 for the user.

It is important that you read the entire content of this procedure prior to the preparation of the infusion solution.

Incompatibilities

This medicine must not be mixed with other medicines except those used for the dilutions.

Shelf life and special precautions for storage

For the pack of Cabazitaxel MSN 60 mg concentrate and solvent

After opening

The concentrate and solvent vials must be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. From a microbiological point of view, the two-step dilution process must take place in controlled and aseptic conditions (see below “Preparation and administration precautions”).

After initial dilution of Cabazitaxel MSN 60 mg concentrate with the **entire** contents of the solvent vial chemical and physical in-use stability has been demonstrated for 1 hour at ambient temperature.

After final dilution in the infusion bag/bottle

Chemical and physical stability of the infusion solution has been demonstrated for 8 hours at ambient temperature (15°C - 30°C) including the 1-hour infusion time and for 48 hours at refrigerated conditions including the 1-hour infusion time.

From a microbiological point of view, the infusion solution should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2°C – 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

Preparation and administration precautions

As for any other antineoplastic agent, caution should be exercised when handling and preparing Cabazitaxel MSN solutions, taking into account the use of containment devices, personal protective equipment (e.g. gloves), and preparation procedures.

If Cabazitaxel MSN, at any step of its handling, should come into contact with the skin, wash immediately and thoroughly with soap and water. If it should come into contact with mucous membranes, wash immediately and thoroughly with water.

Cabazitaxel MSN should only be prepared and administered by personnel trained in handling cytotoxic agents. Pregnant staff should not handle it.

Always dilute the concentrate for solution for infusion with the **entire** supplied solvent before adding to infusion solutions.

Preparation steps

Read this **ENTIRE** section carefully before mixing and diluting. Cabazitaxel MSN requires **TWO** dilutions prior to administration. Follow the preparation instructions provided below.


Note: Both the Cabazitaxel MSN 60 mg/1.5 ml concentrate vial (fill volume: 73.2 mg of cabazitaxel/1.83 ml) and the solvent vial (fill volume: 5.67 ml) contain an overfill to compensate for liquid loss during preparation. This overfill ensures that after dilution with the **ENTIRE** contents of the accompanying solvent, there is solution containing 10 mg/ml cabazitaxel.

The following two-step dilution process must be carried out in an aseptic manner for preparing the solution for infusion.

Step 1: Initial dilution of the concentrate for solution for infusion with the supplied solvent.


Step 1.1

Inspect the concentrate vial and the supplied solvent.
The concentrate solution and the solvent should be clear.



Step 1.2

Using a syringe fitted with a needle, aseptically withdraw the **entire** contents of the supplied solvent by partially inverting the vial.




Step 1.3

Inject the **entire** contents into the corresponding concentrate vial.

To limit foaming as much as possible when injecting the solvent, direct the needle onto the inside wall of the vial of concentrate solution and inject slowly.

Once reconstituted, the resultant solution contains 10 mg/ml of cabazitaxel.



Step 1.4

Remove the syringe and needle and mix manually and gently by repeated inversions until obtaining a clear and homogeneous solution. It could take approximately 45 seconds.



Concentrate-solvent mixture 10 mg/ml

Step 1.5

Let this solution stand for approximately 5 minutes and check then that the solution is homogeneous and clear.

It is normal for foam to persist after this time period.

This resulting concentrate-solvent mixture contains 10 mg/ml of cabazitaxel (at least 6 ml deliverable volume). The second dilution should be done immediately (within 1 hour) as detailed in Step 2.

More than one vial of the concentrate-solvent mixture may be necessary to administer the prescribed dose.




Concentrate-solvent mixture 10 mg/ml

Step 2: Second (final) dilution for infusion

Step 2.1

Aseptically withdraw the required amount of concentrate-solvent mixture (10 mg/ml of cabazitaxel), with a graduated syringe fitted with a needle. As an example, a dose of 45 mg Cabazitaxel MSN would require 4.5 ml of the concentrate solvent mixture prepared following Step 1.


Since foam may persist on the wall of the vial of this solution, following its preparation described in Step 1, it is preferable to place the needle of the syringe in the middle when extracting.



Concentrate-solvent mixture 10 mg/ml


Step 2.2

Inject in a sterile PVC-free container of either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. The concentration of the infusion solution should be between 0.10 mg/ml and 0.26 mg/ml.



Step 2.3

Remove the syringe and mix the content of the infusion bag or bottle manually using a rocking motion.



Step 2.4

As with all parenteral products, the resulting infusion solution should be visually inspected prior to use. As the infusion solution is supersaturated, it may crystallize over time. In this case, the solution must not be used and should be discarded.



The infusion solution should be used immediately. However, in-use storage time can be longer under specific conditions mentioned in section **Shelf life and special precautions for storage** above.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Method of administration

Cabazitaxel MSN is administered as a 1 hour infusion.

An in-line filter of 0.22 micrometer nominal pore size (also referred to as 0.2 micrometer) is recommended during administration.

PVC infusion containers or polyurethane infusion sets should not be used for the preparation and administration of the infusion solution.